Previous Close | 95.56 |
Open | 97.00 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 95.40 - 97.00 |
52 Week Range | 68.65 - 98.00 |
Volume | 1,601 |
Avg. Volume | 47,809 |
Market Cap | 220.672B |
Beta (5Y Monthly) | 0.54 |
PE Ratio (TTM) | 30.92 |
EPS (TTM) | 3.09 |
Earnings Date | N/A |
Forward Dividend & Yield | 3.08 (3.23%) |
Ex-Dividend Date | Mar. 03, 2020 |
1y Target Est | N/A |
Incyte's (INCY) application for pipeline candidate, retifanlimab, for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC) gets Priority Review.
Merck (MRK)/Bayer's (BAYRY) vericiguat gets FDA approval for symptomatic chronic heart failure and reduced ejection fraction
The Zacks Analyst Blog Highlights: Novartis, QUALCOMM, Accenture, MetLife and Electronic Arts